Study S001024

Breast Cancer Survivors With Obesity - Semaglutide's Impact on Preclinical Markers of Cardiovascular Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07769047
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: NOT_YET_RECRUITING
Enrollment: 50
Start: 2026-09-01
Primary completion: 2031-07-30
Lead sponsor: Mayo Clinic
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8
Interventions: PROCEDURE:Biospecimen Collection; PROCEDURE:Dual X-ray Absorptiometry; OTHER:Functional Assessment; BEHAVIORAL:Lifestyle Counseling; DRUG:Semaglutide
Results posted: FALSE
Secondary identifiers: NIH:K23HL183845; OTHER:NCI-2026-04536

Registered primary outcomes

Change in PWV between arms (Aim 1) [Baseline to 24 weeks]
Change in protein expression between arms (Aim 2a) [Baseline to 24 weeks]
Significantly enriched biological pathways and gene sets among DEPs (Aim 2b) [Up to 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.